Th17 cells in alemtuzumab-treated patients: The effect of long-term maintenance immunosuppressive therapy

Transplantation

Volumn 91, Issue 7, 2011, Pages 744-750

  Hester, Joanna ^a   Mills, Natalie ^a   Shankar, Sushma ^a   Carvalho Gaspar, Manuela ^a   Friend, Peter ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CAMPATH 1H; IL 17; Kidney transplant; Sirolimus; T regulatory cells

Indexed keywords

ALEMTUZUMAB; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 17; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RECEPTORS, CCR6; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 79954787760     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820c85dc     Document Type: Article

References (33)

1. Chang SH, Russ GR, Chadban SJ, et al. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007; 84: 611.
2. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
3. Knechtle SJ, Pirsch JDH, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
4. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation- efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
5. Trzonkowski P, ZilvettiM,Friend P, et al. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 2006; 82: 1342.
6. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation byCD28-CD8Tcells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008; 8: 338.
7. Bloom DD, Chang Z, Fechner JH, et al. CD4- CD25- FOXp3- regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8: 793.
8. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9: 1087.
9. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485.
10. Tang JL, Subbotin VM, Antonysamy MA, et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72: 348.
11. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133.
12. Chen L, Ahmed E, Wang T, et al. TLR signals promote IL-6/IL-17- dependent transplant rejection. J Immunol 2009; 182: 6217.
13. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639.
14. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849.
15. Rachitskaya AV, Hansen AM, Horai R, et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180: 5167.
16. Martin B, Hirota K, Cua DJ, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009; 31: 321.
17. Kondo T, Takata H, Matsuki F, et al. Cutting edge: Phenotypic characterization and differentiation of human CD8T cells producing IL-17. J Immunol 2009; 182: 1794.
18. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 345.
19. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809.
20. Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322.
21. Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006; 27: 779.
22. San Segundo D, Lopez-Hoyos M, Fernandez-Fresnedo G, et al. T(H)17 versus Treg cells in renal transplant candidates: Effect of a previous transplant. Transplant Proc 2008; 40: 2885.
23. Deteix C, Attuil-Audenis V, Duthey A, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010; 184: 5344.
24. Heidt S, San D, Chadha R, et al. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010; 15: 456.
25. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am J Transplant 2009; 9: 1816.
26. von Vietinghoff S, Ouyang H, Ley K. Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int 2010; 78: 79.
27. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722.
28. Hendrikx TK, Velthuis JH, Klepper M, et al. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transpl Int 2009; 22: 884.
29. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4-CD25-FOXp3- regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338.
30. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4-CD25- regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390.
31. Jaffar Z, Ferrini ME, Girtsman TA, et al. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur J Immunol 2009; 39: 3307.
32. Chaudhry A, Rudra D, Treuting P, et al. CD4-regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009; 326: 986.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402.